Amneal Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

AMRX$21.28+5.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)

	Three Months Ended March 31,
	2024	2023
Net revenue	$659,191	$557,540
Cost of goods sold	421,131	379,354
Gross profit	238,060	178,186
Selling, general and administrative	112,595	102,096
Research and development	39,298	38,690
Intellectual property legal development expenses	984	1,644
Restructuring and other charges	1,470	510
Change in fair value of contingent consideration	100	2,457
Charges (credit) related to legal matters, net	94,359	(436)
Other operating income	—	(1,224)
Operating (loss) income	(10,746)	34,449
Other (expense) income:
Interest expense, net	(65,703)	(49,315)
Foreign exchange (loss) gain, net	(1,197)	1,901
Increase in tax receivable agreement liability	(1,948)	(826)
Other income, net	4,072	4,365
Total other expense, net	(64,776)	(43,875)
Loss before income taxes	(75,522)	(9,426)
Provision for income taxes	6,156	668
Net loss	(81,678)	(10,094)
Less: Net (income) loss attributable to non-controlling interests	(9,965)	3,151
Net loss attributable to Amneal Pharmaceuticals, Inc.	$(91,643)	$(6,943)
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic and diluted	$(0.30)	$(0.05)
Weighted-average common shares outstanding:
Basic and diluted	307,279	152,109

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.